TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced financial results for the third quarter ending September 30, 2020, and provided a business update.
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the third quarter ending September 30, 2020, and provided a business update.
“As we journey toward the end of 2020, we are excited about the imminent enrollment completion in our EXCELLENCE trial of TLC599 for osteoarthritis pain,” commented George Yeh, President of TLC. “Moreover, we have made tremendous progress in the advancement of our anti-COVID-19 program, TLC19, which has evolved from an incubated idea to being tested in humans in an extremely short amount of time. I would also like to extend a very warm welcome back to Mr. Tom Bliss, who will serve as our new CBO and lead TLC in its commercialization and licensing efforts.”
Clinical Pipeline Update and Upcoming Milestones
- First patient enrollment in Phase I clinical trial of inhalable anti-COVID-19 program. Following approval from Australia’s Human Research Ethics Committee (HREC) and Taiwan’s Food and Drug Administration (TFDA), TLC has promptly enrolled the first patient in the Phase I randomized, vehicle-controlled, blinded study, which will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of inhaled TLC19 (inhalable liposomal hydroxychloroquine) in healthy volunteers. Data from this trial will serve as a basis for subsequent clinical trials in patients with COVID-19.
- ~80% enrollment complete inEXCELLENCE, the Phase III, multi-center, randomized, double-blind, placebo- and active comparator- controlled pivotal study evaluating the efficacy and safety of both a single and a repeated dose of TLC599 for symptomatic knee osteoarthritis. EXCELLENCE remains on-track to complete enrollment of all 500 patients before the end of 2020, with topline data expected in late 2021.
Corporate Highlights
- Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business Officer. Mr. Bliss brings with him ample experience in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, and will take the lead in TLC’s global corporate and business development efforts, with a key focus on the United States.
- Acceptance of Marketing Authorization Application (MAA) for Ampholipad™ in China. The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted TLC’s MAA for Ampholipad™, TLC’s complex generic of Gilead’s AmBisome® (amphotericin B liposome for injection) for the treatment of systemic fungal infections. AmBisome is currently not available in mainland China, creating a rare opportunity for Ampholipad to become available before the brand drug.
- Presented at several global conferences. The management team of TLC presented the latest company updates at Baird’s 2020 Virtual Global Healthcare Conference, HC Wainwright 22nd Annual Global Investment Conference, Cantor Virtual Global Healthcare Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
- Expanded global intellectual property protection to 243 patents, with 156 patents granted and 87 applications worldwide as of September 30, 2020.
Financial Results
Operating revenue for the third quarter of fiscal 2020 was NT$66.1 million (US$2.3 million), a 250.9% increase compared to NT$18.8 million (US$0.6 million) in the third quarter of fiscal 2019. Operating expenses for the third quarter of fiscal 2020 was NT$309.7 million (US$10.7 million), a 56.3% increase compared to NT$198.1 million (US$6.4 million) in the third quarter of fiscal 2019. Net loss for the third quarter of fiscal 2020 was NT$233.7 million (US$8.1 million), compared to a loss of NT$178.4 million (US$5.7 million) in the third quarter of 2019, or a net loss of NT$2.78 (US$0.10) per share for the third quarter of fiscal 2020, compared to a net loss of NT$2.80 (US$0.09) per share for the third quarter of fiscal 2019.
The Company’s cash and cash equivalents were NT$1,015.1 million (US$35.1 million) as of September 30, 2020, compared to NT$1,023.9 million (US$34.2 million) as of December 31, 2019.
Financial Summary
Selected Consolidated Balance Sheet Data
| December 31, 2019 | September 30, 2020 | |||||||||||||||
| NT$000 | US$000 | NT$000 | US$000 | |||||||||||||
| Cash and cash equivalents and time deposit | $ | 1,023,874 | $ | 34,232 | $ | 1,015,093 | $ | 35,064 | ||||||||
| Total current assets | 1,095,614 | 36,631 | 1,158,516 | 40,018 | ||||||||||||
| Total assets | 1,385,978 | 46,339 | 1,486,068 | 51,332 | ||||||||||||
| Total current liabilities | 556,697 | 18,612 | 285,411 | 9,859 | ||||||||||||
| Long-term borrowings | 55,508 | 1,856 | 401,710 | 13,876 | ||||||||||||
| Total liabilities | 664,068 | 22,202 | 763,627 | 26,377 | ||||||||||||
| Total equity | 721,910 | 24,137 | 722,441 | 24,955 | ||||||||||||
Selected Consolidated Statements of Operations Data
| Three-month periods ended September 30, | Nine-month periods ended September 30, | |||||||||||||||||||||||||||||||
| 2019 | 2020 | 2019 | 2020 | |||||||||||||||||||||||||||||
| NT$000 | US$000 | NT$000 | US$000 | NT$000 | US$000 | NT$000 | US$000 | |||||||||||||||||||||||||
| Operating revenue | $ | 18,837 | $ | 607 | $ | 66,095 | $ | 2,283 | $ | 197,194 | $ | 6,351 | $ | 89,845 | $ | 3,104 | ||||||||||||||||
| Operating expenses | ||||||||||||||||||||||||||||||||
| General and administrative expenses | (40,226 | ) | (1,296 | ) | (38,166 | ) | (1,318 | ) | (119,129 | ) | (3,837 | ) | (110,533 | ) | (3,818 | ) | ||||||||||||||||
| Research and development expenses | (157,901 | ) | (5,085 | ) | (271,541 | ) | (9,380 | ) | (611,273 | ) | (19,687 | ) | (692,200 | ) | (23,910 | ) | ||||||||||||||||
| Total operating expenses | (198,127 | ) | (6,381 | ) | (309,707 | ) | (10,698 | ) | (730,402 | ) | (23,524 | ) | (802,733 | ) | (27,728 | ) | ||||||||||||||||
| Loss before income tax | (178,301 | ) | (5,742 | ) | (233,576 | ) | (8,068 | ) | (530,331 | ) | (17,080 | ) | (689,829 | ) | (23,828 | ) | ||||||||||||||||
| Income tax expense | (124 | ) | (4 | ) | (117 | ) | (4 | ) | (1,255 | ) | (40 | ) | (886 | ) | (31 | ) | ||||||||||||||||
| Net loss | $ | (178,425 | ) | $ | (5,746 | ) | $ | (233,693 | ) | $ | (8,072 | ) | $ | (531,586 | ) | $ | (17,120 | ) | $ | (690,715 | ) | $ | (23,859 | ) | ||||||||
| Total other comprehensive loss | $ | (1,675 | ) | $ | (54 | ) | $ | (183 | ) | $ | (6 | ) | $ | (759 | ) | $ | (25 | ) | $ | (1,991 | ) | $ | (69 | ) | ||||||||
| Total comprehensive loss | $ | (180,100 | ) | $ | (5,800 | ) | $ | (233,876 | ) | $ | (8,078 | ) | $ | (532,345 | ) | $ | (17,145 | ) | $ | (692,706 | ) | $ | (23,928 | ) | ||||||||
| Loss per share of common stock | ||||||||||||||||||||||||||||||||
| Basic and diluted loss per share (in dollars) | $ | (2.80 | ) | $ | (0.09 | ) | $ | (2.78 | ) | $ | (0.10 | ) | $ | (8.35 | ) | $ | (0.27 | ) | $ | (8.93 | ) | $ | (0.31 | ) | ||||||||
About TLC
TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage, specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™), including BioSeizer® sustained release technology and NanoX™ active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics targeting areas of unmet medical need in pain management, ophthalmology, oncology and infectious diseases. TLC is consistently ranked top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, without limitation, statements regarding TLC’s expectations regarding the clinical development of TLC’s product candidates, including TLC599 and TLC19, the clinical benefits of TLC’s product candidates, the timing, scope, progress and outcome of TLC’s clinical trials, including TLC599 and TLC19, how sufficient cash and equivalents will be to fund operations, the anticipated timelines for the release of clinical data and progress of TLC’s manufacturing capabilities. Words such as “may,” “believe,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval, and delays or disruptions on our business or clinical trials due to the COVID-19 pandemic. Other risks are described in the Risk Factors section of TLC’s annual report on Form 20-F for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission (the “SEC”) as well as subsequent filings with the SEC. All forward-looking statements are based on TLC’s expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.
TLC Contact: Dawn Chi Corporate Communications dawn@tlcbio.com
